TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35242627

Group type: EXPERIMENTAL
Intervention: Anti-SARS-CoV-2 IgG Abs determination using ELISA kit from NovaLisa targeting recombinant antigen N of the nucleocapsid of SARS-CoV-2.
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Second determination of IgG levels after an average of 4.5 months (IQR 4.0-5.0 months).
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Assessment of severity of infection and hospitalization needs.
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Assessment of symptoms at diagnosis.
Number of subjects: 1500
Study: 35242683

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pyrotinib 400 mg once daily, trastuzumab 4 mg/kg loading dose followed by 2 mg/kg once a week, and albumin-bound paclitaxel 125 mg/m2.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pyrotinib plus trastuzumab and albumin-bound paclitaxel
Number of subjects: 21
Study: 35242798

Group type: EXPERIMENTAL
Intervention: Nutrient formulation containing DHA, ARA, iron, vitamin B12, folic acid, and sphingomyelin from whey protein concentrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control formulation
Number of subjects: 0
Study: 35243302

Group type: EXPERIMENTAL
Intervention: High-dose sevelamer (800 mg thrice daily, titratable up to 1,200 mg thrice daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-dose sevelamer (400 mg thrice daily) with calcium carbonate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-dose sevelamer
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-dose sevelamer
Number of subjects: 60
Study: 35243320

Group type: EXPERIMENTAL
Intervention: Booster CD-JEV dose
Number of subjects: 560

Group type: COMPARATOR
Intervention: Primary CD-JEV vaccination
Number of subjects: 560
Study: 35243418

Group type: EXPERIMENTAL
Intervention: Maternal vaccination
Number of subjects: 0
Study: 35243473

Group type: EXPERIMENTAL
Intervention: Bioengineered human acellular vessels (HAVs) implanted for dialysis access
Number of subjects: 40
Study: 35243592

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 928
Study: 35243870

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOAC)
Number of subjects: 21237

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists
Number of subjects: 21237

Group type: EXPERIMENTAL
Intervention: Antiplatelet drugs
Number of subjects: 21237

Group type: EXPERIMENTAL
Intervention: DOACs in Europe
Number of subjects: 21237

Group type: COMPARATOR
Intervention: DOACs in Asia
Number of subjects: 21237

Group type: COMPARATOR
Intervention: DOACs in Latin America
Number of subjects: 21237
Study: 35243921

Group type: EXPERIMENTAL
Intervention: Hypotension Prediction Score (HYPS)
Number of subjects: 783
Study: 35244208

Group type: EXPERIMENTAL
Intervention: Higher-dose anticoagulants
Number of subjects: 16185

Group type: COMPARATOR
Intervention: Anticoagulants
Number of subjects: 16185
Study: 35244520

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg every 2 weeks for up to 2 years
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 28
Study: 35244681

Group type: EXPERIMENTAL
Intervention: TAA-T infusions at doses of 0.5 to 4 × 10^7/m2
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: TAA-T infusions
Number of subjects: 23
Study: 35244756

Group type: EXPERIMENTAL
Intervention: Bendamustine plus rituximab (R 375 mg/m2)
Number of subjects: 0
Study: 35244820

Group type: EXPERIMENTAL
Intervention: Daily ECG TTM (30 s recordings)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Holter ECG (6-day recordings)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both methods (TTM and Holter ECG)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Daily ECG TTM
Number of subjects: 50

Group type: COMPARATOR
Intervention: Holter ECG
Number of subjects: 50
Study: 35245100

Group type: EXPERIMENTAL
Intervention: Compression garment wear adherence
Number of subjects: 0
Study: 35245205

Group type: EXPERIMENTAL
Intervention: Growth hormone therapy (GHT)
Number of subjects: 69
Study: 35245341

Group type: EXPERIMENTAL
Intervention: Solid formulation of Vitamin B12 delivered during breastfeeding
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Solid formulation of Vitamin B12
Number of subjects: 26
Study: 35245407

Group type: EXPERIMENTAL
Intervention: Inflammatory phenotype
Number of subjects: 2328

Group type: EXPERIMENTAL
Intervention: Meniscus/cartilage phenotype
Number of subjects: 2328

Group type: EXPERIMENTAL
Intervention: Subchondral bone phenotype
Number of subjects: 2328

Group type: EXPERIMENTAL
Intervention: Hypertrophic phenotype (females)
Number of subjects: 2328
Study: 35246024

Group type: EXPERIMENTAL
Intervention: Optimum positive end-expiratory pressure (PEEP) level on Day 1
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Lung recruitability
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Lung overdistension
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Gas exchange improvements in survivors after Day 7
Number of subjects: 116
Study: 35246109

Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure (PAP) adherence during the COVID-19 pandemic
Number of subjects: 8477
Study: 35246222

Group type: EXPERIMENTAL
Intervention: PsA group
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: IMUs
Number of subjects: 21
Study: 35246398

Group type: EXPERIMENTAL
Intervention: Antisense oligonucleotides targeting FUS
Number of subjects: 0
Study: 35246452

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 220
Study: 35246457

Group type: EXPERIMENTAL
Intervention: C1) low tissue turnover
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C2) structural damage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C3) systemic inflammation
Number of subjects: 0
Study: 35246470

Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: upadacitinib 30 mg
Number of subjects: 111
Study: 35246595

Group type: EXPERIMENTAL
Intervention: His bundle pacing (HBP) using the EnSite AutoMap Module for automated assessment of QRS morphology.
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: His-lead stimulation with an intrinsic morphology match score (IMS) ≥ 89%.
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: His-lead stimulation with an IMS between 78 and < 89%.
Number of subjects: 43
Study: 35246776

Group type: EXPERIMENTAL
Intervention: rhIL-7 ex vivo administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no rhIL-7)
Number of subjects: 0
Study: 35247067

Group type: EXPERIMENTAL
Intervention: Improvement of glycaemic control
Number of subjects: 8
Study: 35247086

Group type: EXPERIMENTAL
Intervention: Vorolanib 300 mg orally once daily plus pembrolizumab
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vorolanib 300 mg orally once daily plus nivolumab
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vorolanib 400 mg orally once daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vorolanib 300 mg orally once daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vorolanib (300 or 400 mg)
Number of subjects: 16
Study: 35247191

Group type: EXPERIMENTAL
Intervention: TXA (tranexamic acid)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Markers of in vivo plasmin activation
Number of subjects: 17
Study: 35247274

Group type: EXPERIMENTAL
Intervention: Pexidartinib (200 mg single dose) in subjects with mild hepatic impairment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pexidartinib (200 mg single dose) in subjects with moderate hepatic impairment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Matched healthy controls
Number of subjects: 40
Study: 35247824

Group type: EXPERIMENTAL
Intervention: Dual-task training program
Number of subjects: 11
Study: 35247913

Group type: EXPERIMENTAL
Intervention: Lenalidomide (25 mg as the recommended phase II dose, taken orally for 21 consecutive days of 28-day cycles)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 38
Study: 35247923

Group type: EXPERIMENTAL
Intervention: Active Surveillance (AS)
Number of subjects: 108
Study: 35247983

Group type: EXPERIMENTAL
Intervention: Age 70+
Number of subjects: 4806

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 4806

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus (DM)
Number of subjects: 4806

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD)
Number of subjects: 4806

Group type: EXPERIMENTAL
Intervention: Chronic pulmonary obstructive disease (COPD)
Number of subjects: 4806

Group type: EXPERIMENTAL
Intervention: Pre-existing comorbidities
Number of subjects: 4806
Study: 35248013

Group type: EXPERIMENTAL
Intervention: Unilateral neck irradiation
Number of subjects: 29
Study: 35248212

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir-voxilaprevir (400 mg sofosbuvir, 100 mg velpatasvir, 100 mg voxilaprevir) once daily for 12 weeks
Number of subjects: 40
Study: 35248213

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg) and Velpatasvir (100 mg) once-daily for 12 weeks
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir
Number of subjects: 61
Study: 35248647

Group type: EXPERIMENTAL
Intervention: PDS 10 mg/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PDS 40 mg/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PDS 100 mg/mL
Number of subjects: 0
Study: 35248866

Group type: EXPERIMENTAL
Intervention: FCN-411 (4 mg, 8 mg, 12 mg, and 16 mg once daily until maximum tolerated dose)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: FCN-411 (8 mg once daily, recommended phase II dose)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: FCN-411 (all doses)
Number of subjects: 77
Study: 35249039

Group type: EXPERIMENTAL
Intervention: Waist circumference (WC) obesity definition
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Waist circumference (WC)
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Waist circumference (WC) in low BMI
Number of subjects: 970

Group type: COMPARATOR
Intervention: Body mass index (BMI)
Number of subjects: 970
Study: 35249113

Group type: EXPERIMENTAL
Intervention: β-lactams
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Higher baseline relative abundances of 2 Bacteroides species
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Higher baseline abundance of Lachnospiraceae and amino acid biosynthesis pathways
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Children in the AAD group
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Microbiota compositional profiles
Number of subjects: 66
Study: 35249439

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 170

Group type: COMPARATOR
Intervention: bDMARDs
Number of subjects: 170
Study: 35249485

Group type: EXPERIMENTAL
Intervention: AAV9-coGLB1 gene therapy, injected via caudal vein at 4 weeks of age, sustained expression for up to 32 weeks.
Number of subjects: 0
Study: 35249540

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment for ADHD symptoms (specific medication not detailed)
Number of subjects: 323
Study: 35249706

Group type: EXPERIMENTAL
Intervention: Propofol administered via target-controlled infusion
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Mechanistic pharmacodynamic model
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Empirical models for MAP, HR, and PP
Number of subjects: 36
Study: 35249841

Group type: EXPERIMENTAL
Intervention: Angio-IMR > 40 U
Number of subjects: 285

Group type: COMPARATOR
Intervention: Angio-IMR ≤ 40 U
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Angio-IMR
Number of subjects: 285
Study: 35249968

Group type: EXPERIMENTAL
Intervention: Tocilizumab and dexamethasone
Number of subjects: 111

Group type: COMPARATOR
Intervention: Dexamethasone (control)
Number of subjects: 111
Study: 35250203

Group type: EXPERIMENTAL
Intervention: Pancreatic endoderm cells implanted in nonimmunoprotective macroencapsulation devices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 35250870

Group type: EXPERIMENTAL
Intervention: rhIGF-1 treatment
Number of subjects: 213
Study: 35251038

Group type: EXPERIMENTAL
Intervention: Reduction in GLI activity by small molecule inhibitors or shRNA-mediated knockdown of GLI1 or GLI2.
Number of subjects: 0
Study: 35251315

Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m² in combination with everolimus
Number of subjects: 39
Study: 35251320

Group type: EXPERIMENTAL
Intervention: Ribociclib + endocrine therapy (ET)
Number of subjects: 329
Study: 35251346

Group type: EXPERIMENTAL
Intervention: Tinzaparin administered at an intermediate dose (8,000-12,000 Anti-Xa IU; once daily)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Tinzaparin administered at a prophylactic dose (≤4,500 Anti-Xa IU; once daily)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Tinzaparin (both doses)
Number of subjects: 407
Study: 35252369

Group type: EXPERIMENTAL
Intervention: Rigid Body Rotation (RBR)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Midwall Fibrosis (MWF)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: N-terminal pro brain natriuretic peptide (NT-proBNP)
Number of subjects: 17
Study: 35253296

Group type: EXPERIMENTAL
Intervention: Proactive counselling with easily accessible and approachable healthcare professionals
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Information before rectal cancer surgery
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Counselling after surgery for low anterior resection syndrome
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Healthcare professionals' understanding of major low anterior resection syndrome
Number of subjects: 28
Study: 35253361

Group type: EXPERIMENTAL
Intervention: Defibrotide 6.25 mg/kg IV q6h from the day prior to conditioning through day +21
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Defibrotide 6.25 mg/kg IV q6h
Number of subjects: 25
Study: 35253443

Group type: EXPERIMENTAL
Intervention: Oral antithrombotic agents
Number of subjects: 5324
Study: 35253450

Group type: EXPERIMENTAL
Intervention: HIV infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher standardized nadir CD4 T-cell count
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher levels of standardized TNF-α
Number of subjects: 0
Study: 35254001

Group type: EXPERIMENTAL
Intervention: Phosphine-phosphonium gold(I) complex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phosphine gold(I) complex
Number of subjects: 0
Study: 35254270

Group type: EXPERIMENTAL
Intervention: Automated feedback
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Automated+clinician feedback
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Automated feedback+social network feedback
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 71
Study: 35254385

Group type: EXPERIMENTAL
Intervention: Neoadjuvant PFHPert (palbociclib, trastuzumab, and pertuzumab)
Number of subjects: 28
Study: 35254415

Group type: EXPERIMENTAL
Intervention: Taminadenant (80-640 mg, orally, twice a day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Taminadenant (80-640 mg, orally, twice a day) with spartalizumab (400 mg, i.v., every 4 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study: 35254416

Group type: EXPERIMENTAL
Intervention: INCB086550 (a small-molecule PD-L1 inhibitor)
Number of subjects: 0
Study: 35254525

Group type: EXPERIMENTAL
Intervention: CT acquisition protocols before harmonization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CT acquisition protocols after harmonization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LongComBat harmonized features
Number of subjects: 0
Study: 35254961

Group type: EXPERIMENTAL
Intervention: TMDp patients
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Therapeutic approach
Number of subjects: 54
Study: 35255097

Group type: EXPERIMENTAL
Intervention: ZIKV-exposed infants
Number of subjects: 0

Group type: COMPARATOR
Intervention: ZIKV unexposed infants
Number of subjects: 0
Study: 35255140

Group type: COMPARATOR
Intervention: CoronaVac vaccine (2 doses, 8-12 weeks before enrollment)
Number of subjects: 193
Study: 35255199

Group type: EXPERIMENTAL
Intervention: Daily oral pre-exposure prophylaxis (PrEP)
Number of subjects: 130
Study: 35255536

Group type: EXPERIMENTAL
Intervention: Dupilumab (n = 49)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo (n = 25)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 74
Study: 35255710

Group type: EXPERIMENTAL
Intervention: Arachidonic acid (AA) metabolites measured by mass spectroscopy
Number of subjects: 805
Study: 35255750

Group type: EXPERIMENTAL
Intervention: Zolpidem use before the regulatory change
Number of subjects: 15851

Group type: EXPERIMENTAL
Intervention: Zolpidem use after the regulatory change
Number of subjects: 15851
Study: 35255964

Group type: EXPERIMENTAL
Intervention: INSTI-based regimen (13 subjects)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: INSTI-based regimen
Number of subjects: 19

Group type: COMPARATOR
Intervention: NNRTI-based regimen (6 subjects)
Number of subjects: 19
Study: 35255976

Group type: EXPERIMENTAL
Intervention: Vocational rehabilitation programs (VRP)
Number of subjects: 146
Study: 35256010

Group type: EXPERIMENTAL
Intervention: Multimodal chiropractic care for chronic low back pain (10-week course, mean visits 4.5)
Number of subjects: 40
Study: 35256018

Group type: EXPERIMENTAL
Intervention: Newly developed implementation strategy for active learning
Number of subjects: 2

Group type: COMPARATOR
Intervention: Usual support
Number of subjects: 2
Study: 35256316

Group type: EXPERIMENTAL
Intervention: MF-directed monotherapy (hydroxyurea or ruxolitinib)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 205
Study: 35256495

Group type: EXPERIMENTAL
Intervention: Passive smoking exposure (mother only)
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Passive smoking exposure (father only)
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Passive smoking exposure (both parents)
Number of subjects: 518

Group type: COMPARATOR
Intervention: No passive smoking exposure
Number of subjects: 518
Study: 35256525

Group type: EXPERIMENTAL
Intervention: Lipid-lowering treatment
Number of subjects: 3027

Group type: COMPARATOR
Intervention: No lipid-lowering treatment
Number of subjects: 3027
Study: 35256693

Group type: EXPERIMENTAL
Intervention: Thionamide anti-thyroid drug (titration dosing regimen)
Number of subjects: 0
Study: 35256844

Group type: EXPERIMENTAL
Intervention: Treatment preferences based on avoiding severe nerve damage and longer progression-free survival (PFS)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Cost implications on treatment preferences
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Caregiver preferences
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: BWS exercise results
Number of subjects: 126
Study: 35257522

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT)
Number of subjects: 1036
Study: 35257579

Group type: EXPERIMENTAL
Intervention: Potent small-molecule inhibitors of AAK1 (specific dosage and duration not mentioned)
Number of subjects: 0
Study: 35257639

Group type: EXPERIMENTAL
Intervention: Combined isoflavone compound (CIC)
Number of subjects: 0
Study: 35257644

Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine
Number of subjects: 0
Study: 35257800

Group type: EXPERIMENTAL
Intervention: Celiac plexus radiosurgery with a single 25-Gy fraction
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Celiac plexus radiosurgery
Number of subjects: 18
Study: 35257874

Group type: EXPERIMENTAL
Intervention: Inhaler technology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard inhaler)
Number of subjects: 0
Study: 35257949

Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg/30 mg once daily with pembrolizumab 200 mg every 3 weeks
Number of subjects: 24
Study: 35257974

Group type: EXPERIMENTAL
Intervention: S-ICD with SMART Pass algorithm
Number of subjects: 322

Group type: COMPARATOR
Intervention: S-ICD without SMART Pass algorithm
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: S-ICD in patients with ARVC
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: S-ICD in general
Number of subjects: 322
Study: 35258437

Group type: EXPERIMENTAL
Intervention: COVID-19 Critical Illness Survivors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-COVID-19 Critical Illness Survivors
Number of subjects: 0
Study: 35258461

Group type: EXPERIMENTAL
Intervention: Integrated family planning (FP) and maternal, newborn, and child health (MNCH) services including capacity strengthening of health care providers, counseling of women and girls, sustained provision of supplies, community engagement, and use of health data in decision-making.
Number of subjects: 0
Study: 35258476

Group type: EXPERIMENTAL
Intervention: Positive pressure ventilation (PPV)
Number of subjects: 49
Study: 35258782

Group type: EXPERIMENTAL
Intervention: Noncardiogenic ischemic stroke patients
Number of subjects: 2558

Group type: EXPERIMENTAL
Intervention: Hypertension, dyslipidemia, abnormal HbA1c, intracranial artery stenosis, carotid plaque
Number of subjects: 2558

Group type: EXPERIMENTAL
Intervention: Phlegm-dampness syndrome, blood stasis syndrome, qi deficiency constitution, blood stasis constitution
Number of subjects: 2558
Study: 35258804

Group type: EXPERIMENTAL
Intervention: Pre-implant assessment
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Post-implant assessment
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Overall research engagement
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Qualitative experiences
Number of subjects: 877
Study: 35258841

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 14 mg daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 35258987

Group type: EXPERIMENTAL
Intervention: Temozolomide followed by low-dose ipilimumab and nivolumab
Number of subjects: 33
Study: 35259270

Group type: COMPARATOR
Intervention: BMI <25.0
Number of subjects: 18897

Group type: EXPERIMENTAL
Intervention: BMI 25.0-29.9
Number of subjects: 18897

Group type: EXPERIMENTAL
Intervention: BMI 30.0-39.9
Number of subjects: 18897

Group type: EXPERIMENTAL
Intervention: Higher leisure-time physical activity (LTPA)
Number of subjects: 18897

Group type: EXPERIMENTAL
Intervention: Higher alcohol intake
Number of subjects: 18897

Group type: EXPERIMENTAL
Intervention: Higher dietary BCAAs
Number of subjects: 18897